Pegunigalsidase alfa-iwxj

(Elfabrio®)

Pegunigalsidase alfa-iwxj

Drug updated on 1/4/2024

Dosage FormInjection (intravenous: 20 mg/10 mL (2 mg/mL) solution in a single-dose vial)
Drug ClassHydrolytic lysosomal neutral glycosphingolipid-specific enzyme
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adults with confirmed Fabry disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Elfabrio (pegunigalsidase alfa-iwxj) Prescribing Information. 2023Chiesi Farmaceutici S.p.A., Parma, Italy

Randomized Controlled Trials